Biotechnology

Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity

April 11, 2023 8:15 AM

Total Voting Rights ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 11, 2023 / Biodexa Pharmaceuticals PLC (AIM:BDRX)(Nasdaq:BDRX), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has today issued to investors 11,001,255 new ordinary shares of £0.02 each in the Company ("New Ordinary Shares"), pursuant to exercise notices in respect of 2,200,251 Pre-Funded Warrants received...

Read more

Mosaic ImmunoEngineering Announces Issuance of U.S. Patent Covering Cancer Treatment with Its Lead Immuno-Oncology Candidate MIE-101

April 11, 2023 7:30 AM

- Issued patents include important claims covering methods of treating cancer using MIE-101 as a single agent or in combination with other treatment modalities - - MIE-101 has demonstrated potent, durable, and systemic antitumor activity in multiple preclinical tumor models and in naturally occurring canine tumors - NOVATO, CA / ACCESSWIRE / April 11, 2023 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a...

Read more

Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity

April 6, 2023 6:33 AM

Exercise of Pre-Funded Warrants and Issue of Equity Total Voting Rights ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 6, 2023 / Biodexa Pharmaceuticals PLC (AIM:BDRX)(NASDAQ:BDRX), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has today issued to an investor 4,293,820 new ordinary shares of £0.02 each in the Company ("New Ordinary Shares"), pursuant to exercise notices...

Read more

BioInvent International AB Publishes Annual Report 2022

April 6, 2023 2:50 AM

LUND, SWEDEN / ACCESSWIRE / April 6, 2023 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2022 has been published. The Annual Report is attached to this press release in pdf format and is available on the...

Read more

Abivax Appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair

April 5, 2023 1:45 PM

Marc's appointment bolsters Abivax's position as a leader in the field of chronic inflammatory bowel diseases Corinna zur Bonsen-Thomas steps down as acting Chair and remains a Board Member Prof. Hartmut J. Ehrlich, M.D., retires from the CEO position PARIS, FRANCE / ACCESSWIRE / April 5, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the...

Read more

Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity

April 5, 2023 8:00 AM

Exercise of Pre-Funded Warrants and Issue of Equity Total Voting Rights ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 5, 2023 / Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (AIM:BDRX)(Nasdaq:BDRX), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has today issued to various investors 7,265,825 new ordinary shares of £0.02 each in the Company ("New Ordinary...

Read more

Forecyte Bio, a CGT CDMO, Hosted a Grand Opening for Its Brand-New GMP Facility in Shanghai, Just Two Months After Its Sister Site in the United States

April 5, 2023 7:00 AM

CGT cGMP Production Facilities in US and China SHANGHAI, CHINA / ACCESSWIRE / April 5, 2023 / On March 31, 2023, Forecyte Bio held its opening ceremony for its brand-new, state-of-the-art Cell and Gene Therapy GMP facility in Shanghai, China, marking an important milestone after the successful opening of its United States facility in January. The new facility totals 140,000 sq ft, with a total investment of nearly 40 million USD. It offers...

Read more

Moolec Science Achieves USDA-APHIS Regulatory Status Review Clearance for Molecular Farming Product

April 5, 2023 6:00 AM

LUXEMBOURG / ACCESSWIRE / April 5, 2023 / Moolec Science SA (NASDAQ:MLEC) ("Company" or "Moolec"), a Molecular Farming food-ingredient company, announced today that the Animal and Plant Health Inspection Service ("APHIS") of the U.S. Department of Agriculture ("USDA") has concluded that Moolec's GLA safflower plants pose no greater plant pest risk than non-genetically engineered safflower plants according to regulation found at 7 CFR part 340....

Read more

Biodexa Pharmaceuticals PLC Announces Exercise of Pre-Funded Warrants & Issue of Equity

April 4, 2023 1:45 PM

Total Voting Rights ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 4, 2023 / Biodexa Pharmaceuticals PLC (AIM:BDRX; Nasdaq:BDRX), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has today issued to various investors 24,798,160 new ordinary shares of £0.02 each in the Company ("New Ordinary Shares"), pursuant to exercise notices in respect of 4,959,632 Pre-Funded Warrants...

Read more

AnaBios Acquires Cell Systems, Expands Human Cell Portfolio for Drug Discovery

April 4, 2023 9:00 AM

Acquisition Will Further Enhance AnaBios' Human Tissue & Cells Portfolio, Help Scientists Expedite Drug Discovery & Further Understanding of Cell Biology SAN DIEGO, CA / ACCESSWIRE / April 4, 2023 / AnaBios Corporation today announced the acquisition of Cell Systems, a human primary cell and cell culture media company located in Kirkland, Washington. The purchase of Cell Systems will further enhance AnaBios' unique human tissue and cells...

Read more

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

April 4, 2023 8:45 AM

International name assignment is a key step in Edesa's development and commercialization plans TORONTO, ON / ACCESSWIRE / April 4, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the World Health Organization (WHO) has adopted the international nonproprietary name "paridiprubart" for the company's monoclonal antibody candidate, EB05....

Read more

Enzolytics Announces Progress in the Development and Patenting of Feline Leukemia Monoclonal Antibodies

April 4, 2023 7:00 AM

COLLEGE STATION, TX / ACCESSWIRE / April 4, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/). Enzolytics today announced progress on its ongoing program to produce Monoclonal Antibodies to treat animals by filing a comprehensive patent application covering its identification of conserved neutralizable epitopes on the Feline Leukemia (FeLV) virus. Using the Company's Artificial Intelligence technology, more than 26 immutable...

Read more

BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies

April 4, 2023 5:00 AM

After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers. HEIDLEBERG, GERMANY / ACCESSWIRE / April 4, 2023 / BioMed X, an independent biomedical research institute, announces the start of its new research project - "New Strategies to Enhance the Immunogenicity of Tumors" - in collaboration with Merck. The focus of this new...

Read more

Biovica establishes DiviTum(R) TKa Commercialization Partnership in Italy

April 4, 2023 2:20 AM

UPPSALA, SE / ACCESSWIRE / April 4, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, today announces that the company has signed a commercial partnership agreement with the Italian company, IT Health Fusion, for the commercialization of the DiviTum® TKa assay in Italy. In Italy, some 17,000 women are diagnosed with metastatic breast cancer every year. IT Health Fusion, which is a subsidary...

Read more

Biodexa Pharmaceuticals PLC Announces Issue of Pre-Funded Warrants

April 3, 2023 8:00 AM

Issue of Pre-Funded Warrants ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 3, 2023 / Biodexa Pharmaceuticals PLC (AIM:BDRX.L)(Nasdaq:BDRX), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces that, in accordance with the terms of previously issued Pre-Funded Warrants and the associated Price Adjustment Mechanism under the Private Placement, it has issued an additional 10,508,394...

Read more

Dispatch Media Group Names AmplifyBio a Winner of The Columbus Top Workplaces 2023 Award

April 3, 2023 7:00 AM

WEST JEFFERSON, OH / ACCESSWIRE / April 3, 2023 / AmplifyBio has been awarded a Top Workplaces 2023 honor by Columbus C.E.O. Magazine Top Workplaces. The list is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner Energage LLC. The confidential survey uniquely measures 15 culture drivers that are critical to the success of any organization: including alignment, execution,...

Read more

Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results

March 30, 2023 5:37 PM

~ Corporate Update Call to be Held Tuesday, April 11, 2023 ~ SAN DIEGO, CA / ACCESSWIRE / March 30, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2022. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "Our focus remains...

Read more

Biophytis: The Combined General Meeting Will Be Held on Second Call on April 17, 2023

March 30, 2023 5:20 PM

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 30, 2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today informed that the Extraordinary General Meeting of the company held on...

Read more

First Patients Treated with TISSIUM’s Atraumatic Sutureless Nerve Coaptation System

March 30, 2023 12:00 PM

Clinical Study of TISSIUM's COAPTIUM Connect Atraumatic Sutureless Nerve Coaptation System Is Underway in Australia PARIS, FRANCE and BOSTON, MA / ACCESSWIRE / March 30, 2023 / TISSIUM, a privately-owned medical technology company developing biomorphic programmable polymers for atraumatic tissue reconstruction, announced today the successful implantations of the first patients with its COAPTIUM Connect Sutureless Nerve Coaptation System as part...

Read more

Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity

March 30, 2023 6:20 AM

Exercise of Warrants and Issue of Equity Total Voting Rights ABINGDON, OXFORDSHIRE, UK / ACCESSWIRE / March 30, 2023 / Biodexa Pharmaceuticals PLC (AIM:BDRX)(NASDAQ:BDRX), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has today issued to various investors 6,218,265 new ordinary shares of £0.02 each in the Company ("New Ordinary Shares"), pursuant to exercise notices...

Read more